GlassScriptPhysician profile
Edward G Behrens
NPI 1669479986
$861.97
in general payments reported to CMS, 2019-2025
15 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $14.71 · 2021: $200 · 2022: $78.87 · 2023: $22.33 · 2024: $93.77 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $221.07 | 2025 | Scopis Ent, Xpress Loprofile |
| Medtronic, INC. | $179.84 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $77.01 | 2022-2025 | Dupixent |
| Genzyme Corporation | $64.42 | 2019-2025 | |
| Optinose US, INC. | $58.06 | 2020-2024 | |
| Aerin Medical INC. | $51.29 | 2025 | |
| Intersect Ent, INC. | $42.41 | 2019 | |
| Glaxosmithkline, LLC. | $40.41 | 2022 | |
| Abbvie INC. | $28.64 | 2024 | |
| Neurent Medical Limited | $24.06 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Sunovion Pharmaceuticals INC. | $22.23 | 2019 | |
| Blueprint Medicines Corporation | $20.05 | 2024 | Ayvakit |
| Pharming Healthcare, INC. | $19.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$303,421.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Behrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.